Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
Follow RVTY
Alert me
Revvity Inc. (RVTY) EV/Sales
As of 5 November 2026, Revvity Inc. (RVTY) trades at a EV/Sales of 6.6×. Over the past ten years it has ranged from 2.6× (February 2016) to 7.8× (August 2022); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.8× | (16.53%) |
| FY2024 | 5.7× | (2.52%) |
| FY2023 | 5.8× | (11.03%) |
| FY2022 | 6.6× | (9.39%) |
| FY2021 | 7.2× | 9.70% |
| FY2020 | 6.6× | 50.65% |
| FY2019 | 4.4× | 16.97% |
| FY2018 | 3.7× | (14.75%) |
| FY2017 | 4.4× | 43.35% |
| FY2016 | 3.1× | (5.09%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 6.7× | 33.40% |
| Jun 2026 | 5.0× | 19.78% |
| Mar 2026 | 4.2× | (11.95%) |
| Dec 2025 | 4.8× | 7.86% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICLR ICON PLC compare | 2.4× |
| LH Labcorp Holdings Inc. compare | 2.4× |
| DGX Quest Diagnostics Incorporated compare | 2.8× |
| CRL Charles River Laboratories International, Inc. compare | 4.3× |
| QGEN QIAGEN N.V. compare | 5.4× |
| MEDP Medpace Holdings, Inc. compare | 6.0× |
| RVTY Revvity Inc. | 6.6× |
| ILMN Illumina, Inc. compare | 7.2× |
| GH Guardant Health, Inc. compare | 16.6× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on RVTY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement